letaxaban
Small moleculeexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2007 (NCT00641732)
Timeline
2000s
- Jan 1, 2007
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Coagulation factor XINHIBITOR
F10 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
O=C([C@H](O)CS(=O)(=O)c1ccc2cc(Cl)ccc2c1)N1CCC(N2CCCNC2=O)CC1- Mol. weight
- 479.99 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1095032 ↗
Also known as
- 1-(1-(3-((6-chloronaphthalen-2-yl)sulfonyl)-2-hydroxypropanoyl)piperidin-4-yl)tetrahydropyrimidin-2(1h)-one
- letaxaban
- letaxaban
- letaxaban
- tak442
- tak 442
- tak-442
- tak-442
- tak-442
- tak-442
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00677053 | Phase 2 | Mar 1, 2008 | Takeda |
| NCT00641732 | Phase 2 | Oct 1, 2007 | Takeda |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Takeda | For profit | 2 | 2 | 1 | 2007 |
1 organizations
Page 1 / 1